The appraisals of apalutamide for treating metastatic hormone-sensitive prostate cancer [ID1534] and apalutamide for treating non-metastatic hormone-relapsed prostate cancer [ID1174] have been combined into a single appraisal with the title apalutamide for treating prostate cancer [ID1534]. All information relating to the development of this combined appraisal can be found on this webpage.